Publication Name	World Journal of Gastroenterology
Manuscript ID	8215
Country	Germany

Received	2013-12-22 11:31
Peer-Review Started	2013-12-23 12:19
To Make the First Decision	2014-01-24 12:03
Return for Revision	2014-01-25 16:15
Revised
Second Decision	2014-04-09 08:21
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-09 09:09
Articles in Press	2014-05-23 09:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-09 15:13
Publish the Manuscript Online	2014-06-27 10:37

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells
Manuscript Source	Unsolicited Manuscript
All Author List	Anne Elsner, Falko Lange, Brit Fitzner, Martin Heuschkel, Bernd Joachim Krause and Robert Jaster
Funding Agency and Grant Number	Funding Agency Grant Number Deutsche Forschungsgemeinschaft to RJ
Corresponding Author	Robert Jaster, MD, Department of Medicine Ⅱ, Division of Gastroenterology, University Medicine Rostock, E.-Heydemann-Str. 6, 18057 Rostock, Germany. jaster@med.uni-rostock.de
Key Words	Pancreatic stellate cell; Fibrosis; Erlotinib; Sunitinib; Sorafenib
Core Tip	There are no specific therapies available to treat pancreatic fibrosis, a key feature of chronic pancreatitis and pancreatic cancer. Here we show that three clinically available small molecule kinase inhibitors (SMI), erlotinib, sunitinib and sorafenib, exert antifibrogenic effects in vitro by inhibiting key functions of rat pancreatic stellate cells (PSC), the main source of extracellular matrix proteins in the diseased pancreas. Furthermore, additive effects of the drugs were observed. Our studies also provide insight into molecular mechanisms of SMI action in PSC. We suggest that the antifibrotic efficiency of SMI, especially sorafenib, should be further evaluated in preclinical studies.
Publish Date	2014-06-27 10:37
Citation	Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells. World J Gastroenterol 2014; 20(24): 7914-7925
URL	http://www.wjgnet.com/1007-9327/full/v20/i24/7914.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i24.7914

Full Article (PDF)	WJG-20-7914.pdf
Full Article (Word)	WJG-20-7914.doc
Manuscript File	8215-Review.doc
Answering Reviewers	8215-Answering reviewers.pdf
Copyright License Agreement	8215-Copyright assignment.pdf
Peer-review Report	8215-Peer review(s).pdf
Scientific Editor Work List	8215-Scientific editor work list.doc